Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Express Scripts
Moodys
Dow
Colorcon

Last Updated: January 26, 2020

DrugPatentWatch Database Preview

Ceftazidime - Generic Drug Details

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What are the generic drug sources for ceftazidime and what is the scope of patent protection?

Ceftazidime is the generic ingredient in ten branded drugs marketed by Acs Dobfar, Aurobindo Pharma Ltd, Wockhardt, B Braun, Glaxosmithkline, Teligent, Hospira, Lilly, and Baxter Hlthcare, and is included in sixteen NDAs. Additional information is available in the individual branded drug profile pages.

There are seventeen drug master file entries for ceftazidime. Five suppliers are listed for this compound.

Recent Clinical Trials for ceftazidime

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
AllerganPhase 2
PfizerPhase 2
AllerganPhase 1

See all ceftazidime clinical trials

Pharmacology for ceftazidime
Medical Subject Heading (MeSH) Categories for ceftazidime
Synonyms for ceftazidime
(6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetyl}amino)-8-oxo-3-(pyridinium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(1-hydroxy-2-methyl-1-oxopropan-2-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
(6R,7R)-7-[[(2Z)-2-(2-aminothiazol-4-yl)-2-(1-carboxy-1-methyl-ethoxy)imino-acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}-8-oxo-3-(pyridinium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
1-{[(6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetamido]-2-carboxylato-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl}pyridin-1-ium
72558-82-8
78439-06-2
7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}-3-(pyridinium-1-ylmethyl)-3,4-didehydrocepham-4-carboxylate
AB00513848
AB00513848-02
AB1009357
AC1NUK7U
AKOS015951273
AN-37419
BDBM50420259
BIDD:GT0734
C06889
C22H22N6O7S2
CAZ
Cefprozil, Antibiotic for Culture Media Use Only
Ceftazidim
ceftazidima
Ceftazidima [INN-Spanish]
CEFTAZIDIME (ARGININE FORMULATION)
Ceftazidime (contains ca. 10% Na2CO3)
Ceftazidime (INN)
Ceftazidime (TN)
Ceftazidime anhydrous
Ceftazidime Sodium In Plastic Container
ceftazidimum
Ceftazidimum [INN-Latin]
Ceptaz
Ceptaz (TN)
CHEBI:3508
CHEMBL44354
CS-2810
D07654
DB00438
DTXSID5022770
Fortaz
Fortaz (TN)
Fortaz In Plastic Container
Fortum
GR 20263
HMS2090M13
HY-B0593
MolPort-006-137-763
Pentacef
Q-200811
SCHEMBL36849
Tazicef
Tazidime
Tazidime In Plastic Container

US Patents and Regulatory Information for ceftazidime

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teligent FORTAZ ceftazidime INJECTABLE;INJECTION 050578-004 Jul 19, 1985 AP RX Yes Yes   Start Trial   Start Trial   Start Trial
Lilly TAZIDIME IN PLASTIC CONTAINER ceftazidime INJECTABLE;INJECTION 062739-001 Jul 10, 1986 DISCN No No   Start Trial   Start Trial   Start Trial
Teligent FORTAZ IN PLASTIC CONTAINER ceftazidime sodium INJECTABLE;INJECTION 050634-001 Apr 28, 1989 DISCN No No   Start Trial   Start Trial   Start Trial
Teligent FORTAZ IN PLASTIC CONTAINER ceftazidime sodium INJECTABLE;INJECTION 050634-003 Apr 28, 1989 DISCN Yes No   Start Trial   Start Trial   Start Trial
Aurobindo Pharma Ltd CEFTAZIDIME ceftazidime INJECTABLE;INJECTION 065481-001 May 28, 2010 DISCN No No   Start Trial   Start Trial   Start Trial
Hospira TAZICEF ceftazidime INJECTABLE;INJECTION 062662-002 Mar 6, 1986 AP RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Merck
Boehringer Ingelheim
AstraZeneca
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.